Pharmacy Billing Software With Schedule H1 Register: 2026 Guide

Pharmacy Billing Software With Schedule H1 Register: 2026 Guide

Around the third week of November 2026, one of India's most widely prescribed neuropathic-pain molecules becomes a Schedule H1 drug. If your counter treats Schedule H1 as a handful of sales a week — scribbled into a bound book at 9pm, copied out of the bill book — that arrangement is about to stop working. This is usually the moment a chemist discovers whether their pharmacy billing software with Schedule H1 register support is a real feature or a line on a brochure.

Here is the honest version, which almost no vendor page will give you: the law asks for four fields, not twelve. A paper register is still fully legal. And nothing in the Drugs and Cosmetics Rules obliges you to buy software.

What does change is volume. Pregabalin sells many times a day across a dozen brand names, and most counter staff cannot tell you which of those brands contain it.

In this guide you'll get the exact rule text, the notification and its date arithmetic, why every pregabalin combination is caught, what the Rules say (and don't say) about digital registers, the three settings that turn ordinary billing software into a compliant register, and straight answers on penalties and DPDP.

What a Schedule H1 register legally requires: four fields, not twelve

The duty lives in Rule 65(3)(h) of the Drugs and Cosmetics Rules, 1945. Here it is verbatim, so you can check us rather than trust us:

"the supply of a drug specified in Schedule H1 shall be recorded in a separate register at the time of the supply giving the name and address of the prescriber, the name of the patient, the name of the drug and the quantity supplied and such records shall be maintained for three years and be open for inspection."

That is the complete statutory field list. Four items, three years, open to inspection.

Field	Legally required by Rule 65(3)(h)?
Name and address of the prescriber	Yes
Name of the patient	Yes
Name of the drug	Yes
Quantity supplied	Yes
Batch number	No — good practice, not in the rule
Patient's address	No
Prescriber's registration number	No
Bill / invoice number	No
Brand plus generic name	No

Two things people miss. First, "at the time of the supply" — the record is meant to be created at the counter, not reconstructed from the bill book after closing. Second, note the phrase "a separate register": the H1 record is distinct from your sales register, not a column bolted onto it.

One correction worth stating plainly, because it is propagating: several currently-ranking explainers cite "Rule 65(15A)" as the source of this duty. There is no such register provision. Rule 65(15) is about which descriptions — "Drugstore", "Chemists and Druggists", "Pharmacy" — a licensee may display on the shop. Rule 65(11-A) is an anti-substitution rule. The register duty is 65(3)(h), and you can read the whole of Rule 65 on Indian Kanoon.

The pregabalin notification: what G.S.R. 377(E) says, and exactly when it bites

The provenance chain is public, and it's worth showing so you can verify it yourself on .gov.in hosts:

• DTAB 65th meeting, 20 December 2024 — the recommendation.
• Draft G.S.R. 53(E), 21 January 2026 — public objection period.
• Final G.S.R. 377(E), 13 May 2026 — listed on CDSCO's Gazette Notifications page as "Notification for amendment in Schedule H1 for inclusion of Pregabalin and formulations".
• Published in the Gazette of India Extraordinary, 20 May 2026 — confirmed by PIB (PRID 2263975) and corroborated on DD News.

Pregabalin enters at serial 51. The commencement wording reads: "shall come into force after one eighty days from the date of publication of these rules in the Official Gazette."

Now the arithmetic, because the date matters more than the rule for planning purposes. The clock runs from the 20 May publication date, not the 13 May notification date. Section 9 of the General Clauses Act excludes the first day, so counting starts 21 May. Day 180 lands on 16 November 2026; read strictly as "after" 180 days, 17 November. Sensible answer: treat it as live on or about 16–17 November 2026 and be ready a fortnight early. From today, that is roughly ten weeks.

One caveat on citation hygiene: the short title "Drugs (Second Amendment) Rules, 2026" appears only in secondary reporting. Cite the notification the way CDSCO itself publishes it — G.S.R. 377(E) dated 13 May 2026.

Why every pregabalin combination is caught — the part that changes your workload

Schedule H1 lists the bare molecule: "Pregabalin". That has led a lot of people to assume only plain pregabalin capsules are affected. Read the surrounding rules and that assumption falls apart:

• Rule 65(3)(h) binds "a drug specified in Schedule H1".
• Rule 97 (labelling) binds "drug formulations containing a substance specified in Schedule H1".
• CDSCO's own notification title reads "inclusion of Pregabalin and formulations".
• Punjab's enforcement action was framed against firms "selling drug formulations containing pregabalin" — the state read it at formulation level too.

The conclusion is uncomfortable but clear: every pregabalin-containing product is caught, including the CDSCO-approved fixed-dose combinations — pregabalin with nortriptyline, pregabalin with methylcobalamin — that are staples of Indian neuropathic-pain prescribing. Brands like Maxgalin NT, Norpregalin and Pregalin NT sit in that category.

This is the single most commercially significant fact in this whole topic, and it is why "we'll just add pregabalin to the register" is not a plan. Ask three people at your counter right now which shelf brands contain pregabalin. If they hesitate, your register will have holes in it from day one — and a hole in a register is exactly what an inspection surfaces.

The duty touches nearly every chemist in India, not a narrow slice.

Can a Schedule H1 register be digital? What the Rules actually say

Here is the finding no vendor will put on their pricing page: the Drugs and Cosmetics Rules are silent on electronic registers.

Rule 65 was drafted around physical records. Rule 65(2) even gives the licensee a written election between a prescription register and a cash/credit memo book, notified to the licensing authority. No provision authorises computerised maintenance, no provision prohibits it, and no CDSCO circular or state FDA order mandating software surfaced despite targeted searching.

So the correct statement is:

• No rule requires you to buy pharmacy billing software with a Schedule H1 register. A bound paper book, filled in at the time of supply, is fully compliant.
• Software is a practicality decision, not a legal one — you adopt it because pregabalin volume makes the paper workflow fail, not because a regulator told you to.
• Because the Rules are silent on the electronic alternative, a chemist relying on software should print the register periodically, sign it, and file it. You want a physical artefact to hand an inspector, since the instrument they were trained on is a book.

Treat the digital "requirements" you see listed elsewhere — tamper-proof entries, audit trails naming the editor, batch-level inventory linking, stored prescription images — as vendor features, not statutory obligations. They may be genuinely useful. None of them is mandated by any instrument we could find.

Pharmacy billing software with Schedule H1 register support: three settings, not a new purchase

Picture a real case: a three-counter chemist in a tier-2 city runs a standard Indian pharmacy billing package for GST invoices, batch and expiry tracking. Schedule H1 items — the anti-TB range, a couple of antibiotics, tramadol — go into a paper register under the counter, filled at day's end from the bill book. It works, barely, because H1 is a few lines a week.

Pregabalin breaks that. The fix, in most cases, is configuration and one report — not a new software purchase:

1. Tag every pregabalin-containing SKU in the item master with a Schedule H1 flag. The combinations, not just the plain molecule. This is the step almost everyone misses, and it is the step that decides whether the rest works.
2. Make the billing screen refuse to complete a flagged line until prescriber name, prescriber address and patient name are entered. That is how the record gets created "at the time of the supply", as Rule 65(3)(h) requires — instead of being reconstructed at 9pm.
3. Build one report that prints those four fields, date-ordered, for any date range. That is the register. Print it, sign it, file it.

The outcome: the counter stops maintaining a second book, the nightly reconciliation disappears, and when an inspector asks for the last three months, the answer is a print command rather than an afternoon.

This is the same pattern we keep meeting across sectors. Jewellers hit it with the HUID stock register their billing software has to produce — same vocabulary, same item-master discipline, same inspection at the end of it. The reason it hurts so often is structural: when billing, stock and statutory records live in disconnected systems, every new compliance rule becomes a new manual book instead of a new report.

On vendors, we will be factual and nothing more. GoFrugal's own product blog documents a schedule register that prompts for serial no., bill no., doctor name and address, patient name and address, medicine name and quantity — and notably makes no claim that a digital register is legally required. Marg documents Schedule H/H1 and narcotic register reports. Vyapar documents Schedule H/H1 register maintenance with role-based access. We make no head-to-head or "best" claims, and we publish no prices — the listicles that do are contradicted by the vendors' own documentation.

Punjab is already bound today — and gabapentin is next

Two facts that reframe the deadline.

First: some chemists are already bound, and have been for nearly two years. Punjab district administrations issued prohibitory orders on pregabalin long before the central notification:

• Bathinda district office order banning pregabalin capsules, 28 November 2024 (bathinda.nic.in).
• Ferozepur district notice, "Prohibition of the sale of Pregabalin medicine without a Medical Prescription", running 11 August to 1 October 2025 (ferozepur.nic.in).

Punjab's FDA also directed zonal officers to track manufacture and sale of seven H/H1 drugs, and the state regulator formally asked the Centre to place pregabalin in Schedule H1. If you trade in Punjab, November is not your start date — you have local obligations now.

Second: this will happen again. Draft G.S.R. 745(E), dated 19 August 2026, listed on CDSCO's Gazette Notifications as "Draft notification for inclusion of additional four drugs in Schedule H1", proposes flupentixol, zopiclone, gabapentin and carisoprodol as serials 53–56 — with a 30-day objection period and the same 180-day commencement formula. That consultation is live right now. Gabapentin is prescribed even more widely than pregabalin.

Which is the whole argument for building the process once: a tagged item master, a blocking billing screen and a register report absorb the next notification in an afternoon. A paper book absorbs it by growing another book.

One honest gap: pregabalin sits at serial 51, yet the draft inserts its drugs "after serial number 52", and we could not identify a serial-52 entry. So we will not quote a total count of Schedule H1 drugs — the "51 entries" and "approximately 46 drugs" figures circulating online are both unsafe. Check the current list on CDSCO directly.

Penalties, labels and DPDP: three things people get wrong

On penalties, no fear-selling. We searched state FDA sites and could not find a single order suspending or cancelling a licence specifically for a Schedule H1 register lapse. So the honest framing is: this is a live legal duty you discharge with a register, not a fine that is coming. For completeness, the statutory backdrop is section 28A of the Drugs and Cosmetics Act, 1940 — failure to keep documents: imprisonment up to one year and/or a fine not less than ₹20,000, plus licence action by the State Drugs Controller. The "₹10,000 to ₹1,00,000 penalty range" you'll see quoted on several pages is fabricated; it corresponds to no provision.

Inspectors do act on this molecule, though. In a written reply in the Lok Sabha on 4 April 2025, Union Health Minister J.P. Nadda stated that ₹5.97 crore of pregabalin formulations were seized from 72 premises in Punjab between January and December 2024, with 12 firms' licences cancelled, 46 suspended and 11 complaints filed in court (reported by The Tribune, figures cross-verified by drugscontrol.org). Carry the caveat: all of that was for illegal or unauthorised sale, not a register lapse — pregabalin wasn't in Schedule H1 then. It tells you attention exists. It does not tell you a register fine is coming.

On labels, you relabel nothing. PIB states the duties separately: retailers maintain the register; manufacturers display the prescribed Schedule H1 warning. The red Rx symbol (top-left of the label) and the red-bordered boxed warning sit in Rule 97 and bind the manufacturer or packer — not the chemist. At least one government-hosted page blurs this by saying the labelling requirements "apply to chemists/pharmacies". They don't. The 180-day runway exists largely so manufacturers can change artwork and clear old stock.

On DPDP, keeping the register is not the problem. DPDP Rules 2025 were notified on 13 November 2025, but the substantive obligations are not in force today: Rules 1, 2 and 17–21 commenced on notification; Rule 4 (Consent Managers) on 13 November 2026; Rules 3 and 5–16, 22 and 23 on 13 May 2027. And section 8(7) of the DPDP Act permits retention where required by any law in force — so Rule 65(3)(h)'s three-year retention of patient names lawfully survives a patient's erasure request. The real exposure is different: leaving the register in an unsecured shared spreadsheet, or keeping it well past three years for no reason, becomes a problem from May 2027. Like every MSME handling customer personal data, you have a genuine runway to plan your DPDP posture — use it rather than panicking.

One more operational gap worth knowing: the register needs the prescriber's name and address, and many e-prescriptions arrive without an address. If you dispense against teleconsultation prescriptions, decide now how the counter captures that. The prescriber side of the counter has its own version of this problem, which is why clinic software that captures prescriber and patient details properly makes the chemist's job easier downstream. And to be clear: nothing in ABDM, any e-pharmacy portal or any CDSCO instrument connects to or discharges the Rule 65(3)(h) duty. The register remains a purely local record.

FAQs

Is pregabalin a Schedule H1 drug in India, and from when?

Yes. G.S.R. 377(E) dated 13 May 2026 adds pregabalin to Schedule H1 at serial 51. It was published in the Gazette of India Extraordinary on 20 May 2026 and commences "after one eighty days from the date of publication" — which works out to on or about 16–17 November 2026. Chemists in some Punjab districts are already bound by local prohibitory orders that predate this.

What exactly must a Schedule H1 register contain — which columns are legally required?

Four things, per Rule 65(3)(h): the name and address of the prescriber, the name of the patient, the name of the drug, and the quantity supplied — recorded at the time of supply, in a separate register, kept three years and open for inspection. Batch number, patient address, prescriber registration number and bill number are good practice, not legal requirements.

Can a Schedule H1 register be maintained on a computer, or must it be a paper book?

The Rules are silent on electronic registers — they neither authorise nor prohibit them, and no CDSCO circular mandating software could be found. A bound paper register is fully compliant. If you use software, print the register periodically, sign it and file it, so you have a physical record for an inspector.

Do pregabalin combination medicines also need a Schedule H1 register entry?

Yes, in our reading. Schedule H1 lists the molecule, but Rule 97 binds formulations "containing" a Schedule H1 substance, CDSCO's notification title says "Pregabalin and formulations", and Punjab enforced against products "containing pregabalin". Tag every pregabalin-containing SKU — including the nortriptyline and methylcobalamin combinations — in your item master.

What is the actual penalty for not maintaining a Schedule H1 register?

Section 28A of the Drugs and Cosmetics Act, 1940 covers failure to keep documents: imprisonment up to one year and/or a fine not less than ₹20,000, alongside licence action by the State Drugs Controller. We could not find any published state order suspending a licence specifically for a Schedule H1 register lapse — so treat this as a duty to discharge, not an imminent fine. Ignore the "₹10,000–₹1,00,000" range circulating online; it matches no provision.

Which other drugs are being added to Schedule H1 in 2026?

Draft G.S.R. 745(E) dated 19 August 2026 proposes flupentixol, zopiclone, gabapentin and carisoprodol as serials 53–56, with a 30-day objection window and the same 180-day commencement formula. It is a draft under consultation, not yet law — but gabapentin is prescribed even more widely than pregabalin, so build the process once.

Getting your counter ready before November

Cybiqon AI Solutions builds websites, apps and AI automation for Indian MSMEs — and a large part of that work is exactly this: taking a compliance rule and turning it into a setting, a validation and a report inside software a business already owns.

If you run a chemist shop, a distribution business or a small pharmacy chain, the pregabalin change is a good excuse to audit three things: is your item master tagged, does your billing screen enforce capture at the point of supply, and can you print a signed register for any date range in one click? If the answer to any of those is no, we can help you fix it — usually by configuring or extending what you have, not replacing it.

Have a look at what we do at cybiqon.in, or just talk to us: +91 9250711473 or [email protected]. No obligation, and we'll tell you honestly if you don't need us.

The bottom line

Choosing pharmacy billing software with Schedule H1 register capability is not really a software decision — it's a workflow decision with a deadline attached. The law asks for four fields, captured at the time of supply, kept three years. Paper is legal. What changes on or about 16–17 November 2026 is volume, and the trap is the combination products almost nobody has tagged. Fix the item master, make the billing screen insist, and build the report. Then gabapentin, if it lands, costs you an afternoon instead of another book. If you'd like a hand, Cybiqon is a call away.